secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001213900-25-075272
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX reports Q2 net loss $6.0M, cash $15.2M; BX211 shows >40% wound reduction in Phase 2
--------------------------------------------------------------------------------

- Cash and restricted cash $15.2M at June 30, 2025; estimated to fund ops into Q1 2026.
- Net loss $6.0M for Q2 2025 vs. income $4.5M in Q2 2024, driven by warrant fair value change.
- BX211 Phase 2: >40% wound size reduction vs placebo in diabetic foot osteomyelitis; registrational study planning underway.
- BX004 Phase 2b in CF successfully initiated dosing; topline results expected Q1 2026.
- Nature Comm. publication: BX004 showed ~500-fold (2.7 log₁₀) bacterial reduction vs placebo with no resistance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025075272/0001213900-25-075272-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025075272/ea0253022-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-075272

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer